Evan Weber
@evanweberphd.bsky.social
Assistant Professor @pennmedicine.bsky.social and @childrensphila.bsky.social. My lab is focused on developing approaches to enhance CAR T cell fitness.
www.theweberlab.org
www.theweberlab.org
Pinned
Evan Weber
@evanweberphd.bsky.social
· Dec 17
2025 Spring Scientific
The 2025 SITC Spring Scientific, Cellular Therapy for Solid Tumors, will address the recent advances in adoptive cellular therapy for solid tumors and rate-limiting challenges that impede bringing the...
www.sitcancer.org
Calling all cell therapists!
The SITC Spring Scientific on Cellular Therapy for Solid Tumors takes place March 12-14 2025 in sunny San Diego. Fantastic speaker lineup, and slots for abstract talks
www.sitcancer.org/education/sp...
Early registration deadline is THIS FRIDAY. Abstracts due Jan 8th.
The SITC Spring Scientific on Cellular Therapy for Solid Tumors takes place March 12-14 2025 in sunny San Diego. Fantastic speaker lineup, and slots for abstract talks
www.sitcancer.org/education/sp...
Early registration deadline is THIS FRIDAY. Abstracts due Jan 8th.
Our new, comprehensive review on all things CAR T cell persistence is officially published in @cellcellpress.bsky.social @cp-trendscancer.bsky.social. Fantastic work from lead authors Kat Mueller and Jeremy Grenier.
Link to the full article:
www.cell.com/trends/cance...
Link to the full article:
www.cell.com/trends/cance...
CAR T cell persistence in cancer
Chimeric antigen receptor T cell (CAR T) therapies are ‘living drugs’ in which T cells
are genetically engineered to recognize and kill cancer cells. A major barrier to
progress for CAR T targeting li...
www.cell.com
October 17, 2025 at 6:22 PM
Our new, comprehensive review on all things CAR T cell persistence is officially published in @cellcellpress.bsky.social @cp-trendscancer.bsky.social. Fantastic work from lead authors Kat Mueller and Jeremy Grenier.
Link to the full article:
www.cell.com/trends/cance...
Link to the full article:
www.cell.com/trends/cance...
Reposted by Evan Weber
We are experiencing an assault on science unparalleled by anything I’ve seen in my life. It’s not one issue or another anymore, the entire institution is under attack by the most powerful individuals in the country.
This Friday, where will you be?
standupforscience2025.org
This Friday, where will you be?
standupforscience2025.org
March 2, 2025 at 4:27 PM
We are experiencing an assault on science unparalleled by anything I’ve seen in my life. It’s not one issue or another anymore, the entire institution is under attack by the most powerful individuals in the country.
This Friday, where will you be?
standupforscience2025.org
This Friday, where will you be?
standupforscience2025.org
Reposted by Evan Weber
Any speculation why big pharma and biotech industries have been so quiet about the current defunding of biomedical research?
(which also means the defunding of biomedical research training)
(which also means the defunding of biomedical research training)
March 3, 2025 at 12:30 AM
Any speculation why big pharma and biotech industries have been so quiet about the current defunding of biomedical research?
(which also means the defunding of biomedical research training)
(which also means the defunding of biomedical research training)
Reposted by Evan Weber
With an Ro of 12-18, a mortality rate of about 1-2/10,000 and an MMR vaccination rate in this area of Texas at 82% we should expect to see this expand to many 1000 cases quickly and, unfortunately, potential deaths.
February 22, 2025 at 4:49 PM
With an Ro of 12-18, a mortality rate of about 1-2/10,000 and an MMR vaccination rate in this area of Texas at 82% we should expect to see this expand to many 1000 cases quickly and, unfortunately, potential deaths.
Reposted by Evan Weber
Honored to have our recently published first-in-human phase 1 clinical trial of repeatedly dosed intracerebroventrocular B7-H3 #CARTcells for children with #DIPG highlighted in @theaacr.bsky.social and #CancerDiscovery Research Watch ❤️🔬
BrainChild-03 Trial Supports Safety of B7-H3 CAR T-cell Therapy for DIPG
Main Finding: A phase I trial supported the safety and feasibility of repeated intracranial infusions of B7-H3 CAR T cells for DIPG.Concept: B7-H3 is an immunoregulatory protein expressed on the surfa...
aacrjournals.org
January 28, 2025 at 6:48 PM
Honored to have our recently published first-in-human phase 1 clinical trial of repeatedly dosed intracerebroventrocular B7-H3 #CARTcells for children with #DIPG highlighted in @theaacr.bsky.social and #CancerDiscovery Research Watch ❤️🔬
Reposted by Evan Weber
My weekend with immunologists devising new strategies to treat cancer, allergy, Alzheimer’s, autoimmunity and infection. The WH has just paused peer-reviewed NIH funding that pays for these studies. If you care about human life, write your representatives. Demand that NIH funding is restored asap.
January 28, 2025 at 5:27 AM
My weekend with immunologists devising new strategies to treat cancer, allergy, Alzheimer’s, autoimmunity and infection. The WH has just paused peer-reviewed NIH funding that pays for these studies. If you care about human life, write your representatives. Demand that NIH funding is restored asap.
Reposted by Evan Weber
Excited and grateful that our initial report on temperature-sensitive protein switches is now published
@naturemethods.bsky.social Co-led by PhD students Will Benman and @dennishuang.bsky.social
www.nature.com/articles/s41...
Brief thread:
@naturemethods.bsky.social Co-led by PhD students Will Benman and @dennishuang.bsky.social
www.nature.com/articles/s41...
Brief thread:
January 24, 2025 at 11:53 AM
Excited and grateful that our initial report on temperature-sensitive protein switches is now published
@naturemethods.bsky.social Co-led by PhD students Will Benman and @dennishuang.bsky.social
www.nature.com/articles/s41...
Brief thread:
@naturemethods.bsky.social Co-led by PhD students Will Benman and @dennishuang.bsky.social
www.nature.com/articles/s41...
Brief thread:
Starting off 2025 inspired by this fantastic interview with @geochurch.bsky.social
Beyond George's intellect and scientific genius, he is so adept at communicating complex ideas about teamwork, creativity, discovery, and innovation. Thanks @nightsciencepod.bsky.social @itaiyanai.bsky.social!
Beyond George's intellect and scientific genius, he is so adept at communicating complex ideas about teamwork, creativity, discovery, and innovation. Thanks @nightsciencepod.bsky.social @itaiyanai.bsky.social!
January 2, 2025 at 2:24 PM
Starting off 2025 inspired by this fantastic interview with @geochurch.bsky.social
Beyond George's intellect and scientific genius, he is so adept at communicating complex ideas about teamwork, creativity, discovery, and innovation. Thanks @nightsciencepod.bsky.social @itaiyanai.bsky.social!
Beyond George's intellect and scientific genius, he is so adept at communicating complex ideas about teamwork, creativity, discovery, and innovation. Thanks @nightsciencepod.bsky.social @itaiyanai.bsky.social!
Reposted by Evan Weber
I’m excited to be a co-organizer this year for the SITC Winter School, where we focus on the core principles of #TumorImmunology & #CancerImmunotherapy. We’ll also be discussing advancements in drug development, biomarkers, & clinical trials. More info here: go.sitcancer.org/3XOCoBh Please join us!
December 23, 2024 at 4:10 PM
I’m excited to be a co-organizer this year for the SITC Winter School, where we focus on the core principles of #TumorImmunology & #CancerImmunotherapy. We’ll also be discussing advancements in drug development, biomarkers, & clinical trials. More info here: go.sitcancer.org/3XOCoBh Please join us!
Calling all cell therapists!
The SITC Spring Scientific on Cellular Therapy for Solid Tumors takes place March 12-14 2025 in sunny San Diego. Fantastic speaker lineup, and slots for abstract talks
www.sitcancer.org/education/sp...
Early registration deadline is THIS FRIDAY. Abstracts due Jan 8th.
The SITC Spring Scientific on Cellular Therapy for Solid Tumors takes place March 12-14 2025 in sunny San Diego. Fantastic speaker lineup, and slots for abstract talks
www.sitcancer.org/education/sp...
Early registration deadline is THIS FRIDAY. Abstracts due Jan 8th.
2025 Spring Scientific
The 2025 SITC Spring Scientific, Cellular Therapy for Solid Tumors, will address the recent advances in adoptive cellular therapy for solid tumors and rate-limiting challenges that impede bringing the...
www.sitcancer.org
December 17, 2024 at 6:52 PM
Calling all cell therapists!
The SITC Spring Scientific on Cellular Therapy for Solid Tumors takes place March 12-14 2025 in sunny San Diego. Fantastic speaker lineup, and slots for abstract talks
www.sitcancer.org/education/sp...
Early registration deadline is THIS FRIDAY. Abstracts due Jan 8th.
The SITC Spring Scientific on Cellular Therapy for Solid Tumors takes place March 12-14 2025 in sunny San Diego. Fantastic speaker lineup, and slots for abstract talks
www.sitcancer.org/education/sp...
Early registration deadline is THIS FRIDAY. Abstracts due Jan 8th.
Reposted by Evan Weber
Here is link to Shixin's new paper: www.science.org/doi/epdf/10....
Nutrient-driven histone code determines exhausted CD8+ T cell fates
ACLY-deficient CAR T cells targeting the tumor-associated antigen disialoganglioside GD2 (GD2 CAR T cells) also resisted acquiring TEX-like properties, exhibiting reduced CD39 expression when co-cultu...
www.science.org
December 14, 2024 at 3:53 PM
Here is link to Shixin's new paper: www.science.org/doi/epdf/10....
Reposted by Evan Weber
Fascinating study where they label CAR T cells and follow their trafficking in patients! Immediate biodistribution is to the liver and spleen, and they can see whether the Car goes into extramedullary masses. What explains differences between patients?
Up next, the #ASH24 #MyelomaSky **Clinical Abstracts - RRMM @ash-hematology.bsky.social
1029 CAR-T Cell Therapy in Advanced Myeloma with EMD In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI
ash.confex.com/ash/2024/web...
1029 CAR-T Cell Therapy in Advanced Myeloma with EMD In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI
ash.confex.com/ash/2024/web...
Paper: CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an <em>In Vivo</Em> Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-...
ash.confex.com
December 6, 2024 at 2:42 PM
Fascinating study where they label CAR T cells and follow their trafficking in patients! Immediate biodistribution is to the liver and spleen, and they can see whether the Car goes into extramedullary masses. What explains differences between patients?
Reposted by Evan Weber
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
www.cell.com/cancer-cell/...
www.cell.com/cancer-cell/...
December 6, 2024 at 3:47 AM
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
www.cell.com/cancer-cell/...
www.cell.com/cancer-cell/...
Reposted by Evan Weber
ICYMI - over the summer Maria Parkhurst from our branch published one of the first reports of clinical responses after adoptive cell transfer of TCR engineered private neoantigen (tumor mutation) targeting T cells in metastatic cancer patients 🧪🦠🔬🩺 1/3 #Immunosky
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results - Nature Medicine
Preliminary findings in seven patients with mismatch repair-proficient metastatic colorectal cancer who were treated in the context of a phase 2 trial show that adoptive transfer of autologous periphe...
www.nature.com
November 24, 2024 at 5:02 PM
ICYMI - over the summer Maria Parkhurst from our branch published one of the first reports of clinical responses after adoptive cell transfer of TCR engineered private neoantigen (tumor mutation) targeting T cells in metastatic cancer patients 🧪🦠🔬🩺 1/3 #Immunosky
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Evan Weber
🚨NEW🧪: TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function - #CARTCell #immunotherapy #TCell #tcellrx #immunology www.science.org/doi/10.1126/...
TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function
Modulation of exhausted CD8+ T cell differentiation by targeting TET2 improves therapeutic potential of CAR T cells in cancer.
www.science.org
November 19, 2024 at 12:45 PM
🚨NEW🧪: TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function - #CARTCell #immunotherapy #TCell #tcellrx #immunology www.science.org/doi/10.1126/...
Reposted by Evan Weber
Postdocs in Immuno-Oncology: consider this awesome career development opportunity! You get to network with accomplished faculty and rising start peers in preparation for running a research group!
Info: irvingcancerimmunologysymposium.com
Application link: docs.google.com/forms/d/e/1F...
Info: irvingcancerimmunologysymposium.com
Application link: docs.google.com/forms/d/e/1F...
November 15, 2024 at 8:03 PM
Postdocs in Immuno-Oncology: consider this awesome career development opportunity! You get to network with accomplished faculty and rising start peers in preparation for running a research group!
Info: irvingcancerimmunologysymposium.com
Application link: docs.google.com/forms/d/e/1F...
Info: irvingcancerimmunologysymposium.com
Application link: docs.google.com/forms/d/e/1F...
Reposted by Evan Weber
In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma https://www.biorxiv.org/content/10.1101/2024.11.19.624352v1
In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma https://www.biorxiv.org/content/10.1101/2024.11.19.624352v1
Chimeric antigen receptor (CAR) T cells are highly effective in hematologic malignancies. However, l
www.biorxiv.org
November 20, 2024 at 2:18 AM
In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma https://www.biorxiv.org/content/10.1101/2024.11.19.624352v1
Reposted by Evan Weber
I made a starter pack for those of us interested in or working on T cells. Let me know if you would like to be added or know somebody that should be added.
Looking forward to scientific discussions and updates on our favorite immune cell type!
Looking forward to scientific discussions and updates on our favorite immune cell type!
November 18, 2024 at 5:19 PM
I made a starter pack for those of us interested in or working on T cells. Let me know if you would like to be added or know somebody that should be added.
Looking forward to scientific discussions and updates on our favorite immune cell type!
Looking forward to scientific discussions and updates on our favorite immune cell type!
Reposted by Evan Weber
Inspired by the other amazing starter packs - here's one for cancer researchers!
I tried to make this broad - from immunology to genomics to cell biology and so much more..
This list also includes organizations & institutes supporting cancer researchers 🧪🔬⚕️🩺
Hope its useful!
go.bsky.app/FEoaJMc
I tried to make this broad - from immunology to genomics to cell biology and so much more..
This list also includes organizations & institutes supporting cancer researchers 🧪🔬⚕️🩺
Hope its useful!
go.bsky.app/FEoaJMc
November 14, 2024 at 9:44 PM
Inspired by the other amazing starter packs - here's one for cancer researchers!
I tried to make this broad - from immunology to genomics to cell biology and so much more..
This list also includes organizations & institutes supporting cancer researchers 🧪🔬⚕️🩺
Hope its useful!
go.bsky.app/FEoaJMc
I tried to make this broad - from immunology to genomics to cell biology and so much more..
This list also includes organizations & institutes supporting cancer researchers 🧪🔬⚕️🩺
Hope its useful!
go.bsky.app/FEoaJMc
Reposted by Evan Weber
🐦➡️🦋 Looking to rebuild your network on Bluesky by reconnecting with your existing X/Twitter contacts? The Skylink browser extension makes it easy!
chromewebstore.google.com/detail/sky-f...
Thanks @jmschreiber91.bsky.social!
#scicomm #cancer #tumorimmunology
chromewebstore.google.com/detail/sky-f...
Thanks @jmschreiber91.bsky.social!
#scicomm #cancer #tumorimmunology
Sky Follower Bridge - Chrome Web Store
Instantly find and follow the same users from your Twitter follows on Bluesky.
chromewebstore.google.com
November 17, 2024 at 10:56 AM
🐦➡️🦋 Looking to rebuild your network on Bluesky by reconnecting with your existing X/Twitter contacts? The Skylink browser extension makes it easy!
chromewebstore.google.com/detail/sky-f...
Thanks @jmschreiber91.bsky.social!
#scicomm #cancer #tumorimmunology
chromewebstore.google.com/detail/sky-f...
Thanks @jmschreiber91.bsky.social!
#scicomm #cancer #tumorimmunology